ArticleFrontiers in cellular and infection microbiology2025
Systems pharmacology-based optimization of Ma Xing Shi Gan components for the enhanced treatment of chick health issues caused by infectious bronchitis virus.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Effects of Macleaya Cordata Extract on LPS-Induced Intestinal Inflammation and Diarrhea via Modulation of Gut Microbiota.Animals : an open access journal from MDPI · 2026Article
- Herbal medicines against avian infectious bronchitis virus: shared host-directed and multi-stage antiviral pathways.Frontiers in veterinary science · 2026Review
- Effects of dietary fermented passion fruit (Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Infectious bronchitis virus (IBV) imposes severe economic burdens on the poultry industry, and current treatments face challenges in efficacy and sustainability, necessitating the development of novel therapeutic strategies. To address this, this study employed the Traditional Chinese Medicine Inheritance Computing Platform (TCMICS) to collect clinical prescriptions for IBV treatment, based on which two optimized versions of the traditional Chinese medicine Maxing Shigan Decoction (MXSG), namely MXSG-mix1 and MXSG-mix2, were designed. In vitro cell culture and in vivo chicken model experiments were then carried out, including egg testing, clinical symptom observation, immune function analysis, and viral load quantification, to assess the antiviral activity of the optimized formulations. Methods: To explore the underlying mechanisms, liquid chromatography-mass spectrometry (LC-MS) was combined with network pharmacology to identify 28 active compounds in MXSG-mix and 47 key genes involved in viral replication, inflammation, and apoptosis pathways. Furthermore, molecular docking and RT-qPCR were performed, which confirmed that MXSG-mix downregulated BCL2 expression and interacted with AKT1 and CASP3, thus inhibiting IBV-induced cell apoptosis. Results and discussion: The results showed that both MXSG-mix1 and MXSG-mix2 exhibited superior anti-IBV activity compared to traditional MXSG, effectively reducing viral load and improving immune responses in vivo. In conclusion, integrating TCMICS, LC-MS, and network pharmacology offers a novel paradigm for developing veterinary TCM formulations. The optimized MXSG-mix shows potential as an effective, multi-target therapeutic against IBV, providing valuable insights for future anti-viral drug development in poultry medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.